Celestial is developing a novel mRNA platform technology licensed in from Harvard. Celestial’s plan is to develop a new class of mRNA vaccines and therapeutics that are safer, more efficacious & durable. Celestial’s novel platform may have the potential to result in a lucrative exit without the need of extensive further funding.